BMS blocks biosimilar version of blockbuster cancer drug in India

Delhi High Court has granted an interim injunction against Zydus Lifesciences over the company’s proposed nivolumab product | BMS’s Indian patent covering the monoclonal antibody expires in May 2026.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

Americas

Court upholds $83m sequencing verdict and sets royalty rate

17 June 2026 A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.

Americas

Amgen and subsidiary dealt $20m blow over rodent antibody tech

15 June 2026 Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.

Americas

Moderna: BioNTech is claiming work ‘it never did’

12 June 2026 In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.

More features

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Boston Scientific expands dispute with J&J unit over cardiac-access technology

Brazilian firm appoints patent strategist to lead department

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

Foley Hoag adds two partners in Denver expansion

BMS blocks biosimilar version of blockbuster cancer drug in India

More on this story

Editor's picks

Editor's picks

More features